Article Text

other Versions

Randomised controlled trial
Subcutaneous liraglutide reduces weight and improves metabolic control in obese participants
  1. Kyaw Soe,
  2. Kathleen M Dungan
  1. The Ohio State University, Columbus, Ohio, USA
  1. Correspondence to : Dr Kathleen M Dungan, The Ohio State University, 5th floor, McCampbell Hall, 1581 Dodd Dr, Columbus, OH 43210, USA; kathleen.dungan{at}

Statistics from

Commentary on: OpenUrlCrossRefPubMed


Obesity is a major health problem of the 21st century and has been one of the primary contributors to the rising prevalence of type 2 diabetes mellitus (T2DM). A 5–10% loss of total body weight can reduce risk of T2DM onset.1 However, it is challenging to achieve and maintain weight loss that is sufficient for sustained metabolic benefits. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was initially developed for treatment of hyperglycaemia in patients with T2DM. It was also noted to have non-glycaemic benefits such as weight loss2 and …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.